Esperion (ESPR) AI Stock Analysis

• Market Cap: $645.47M
• Dividend Yield: N/A
• Average Volume (3M): 3.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.52
• Revenue Growth: 2.83%
• EPS Growth: 13.61%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.22
• Shares Outstanding: 239,063,430
• 10 Day Avg. Volume: 4,841,918
• 30 Day Avg. Volume: 3,919,212
• PEG Ratio: 0.56
• Price to Book (P/B): -2.55
• Price to Sales (P/S): 1.91
• P/FCF Ratio: -59.60
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 4.34
• Enterprise Value/Ebitda: 8.25
• 1Y Price Target: $7.30
• Price Target Upside: 170.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.17
• Revenue Forecast (FY): $413.92M

• Rating: 47 Neutral
• Price Target: $2.50 ▼(-7.41% Downside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is held down primarily by a still-fragile financial profile (net losses, negative free cash flow, and negative equity) and weak technical momentum (below key moving averages with negative MACD). These are partly offset by a positive earnings-call backdrop highlighting accelerating revenue, expanded access/prescribing, and long-dated generic protection, plus a strategically positive but execution-sensitive acquisition.

Positive Factors

Re-accelerating revenue and commercial traction

Sustained double-digit top-line re-acceleration and a growing prescriber base indicate durable commercial adoption of NEXLETOL/NEXLIZET. That expanding revenue mix and repeat prescription growth support longer-term sales visibility and scale for investment in marketing and R&D over the next 2–6 months and beyond.

Long-dated generic protection and guideline validation

Contractual generic protection through 2040 plus guideline inclusion materially preserves pricing and market share for the franchise. These structural protections reduce near- to mid-term erosion risk, underpin long-horizon revenue streams, and strengthen bargaining leverage with payers and partners.

Strategic portfolio expansion via Corstasis acquisition

Acquiring an FDA-approved, complementary cardiovascular product diversifies revenue beyond LDL-C therapies and leverages Esperion's existing commercial infrastructure. This expands addressable markets, creates cross-selling opportunities, and supports strategic growth ambitions if integration executes as planned.

Negative Factors

Persistent negative shareholders' equity

A sustained negative equity position constrains financial flexibility, limits balance-sheet resilience, and raises dependence on external financing for growth or M&A. Even with lower debt, negative equity reduces capacity to absorb operational volatility and can increase borrowing costs or covenant risks.

Negative operating and free cash flow

Ongoing negative cash generation forces reliance on external capital or asset monetization to fund operations and strategic initiatives. Despite improvement versus earlier years, material negative FCF and sensitivity to working capital undermine self-funded growth and increase execution risk for commercialization and acquisitions.

Multi-year net losses despite improving margins

While operating profitability improved, persistent net losses and a history of sizable deficits signal earnings quality issues. Until net income turns sustainably positive, the company faces pressure to fund operations externally, limiting capacity to reinvest and making long-term profitability outcomes uncertain.

Esperion Business Overview & Revenue Model

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

How the Company Makes Money

Esperion primarily generates revenue from commercial sales of its cholesterol-lowering medicines and from collaboration/partner economics tied to ex-U.S. markets. Key revenue streams include: (1) Product revenue from U.S. sales of NEXLETOL and NEXLIZET, where Esperion records revenue based on shipments/sales to customers net of typical deductions (e.g., rebates, chargebacks, returns, and other allowances). (2) Collaboration and license revenue from partnerships that commercialize bempedoic acid products outside the U.S.; these arrangements can include upfront payments, milestone payments (e.g., regulatory or commercial milestones), and ongoing royalties or profit-sharing based on partner sales, depending on contract terms. (3) Other potential partnering income (if applicable in a given period) may include reimbursement of certain costs or fees related to collaborative development and commercialization activities. Significant factors influencing earnings include prescription demand in the U.S. market (payer coverage and formulary placement can affect net pricing and volume), the performance of ex-U.S. partners (which impacts royalties/profit share and milestones), and the timing/recognition of any contractual milestone events.

Esperion Financial Statement Overview

Summary

Operations are improving (2025 revenue up ~33% and EBITDA margin ~15%), but profitability and funding remain pressured with continued net losses, negative free cash flow, and persistent negative shareholders’ equity despite lower debt in 2025.

Income Statement

Revenue growth re-accelerated in 2025 (annual revenue up ~33% vs. ~2% in 2024), and operating profitability improved materially versus 2022–2023, with EBITDA margin reaching ~15% in 2025. However, net income remains negative (about -6% net margin in 2025), and the company has a multi-year track record of sizable losses prior to the recent improvement, which keeps overall earnings quality and consistency below average.

Balance Sheet

The balance sheet is constrained by persistent negative shareholders’ equity across all periods provided, indicating accumulated deficits and limited financial flexibility. While total debt declined sharply in 2025 versus 2024, leverage remains a key risk given the negative equity position, and the capital structure leaves less cushion against operating volatility typical in specialty pharma.

Cash Flow

Cash generation remains weak, with operating cash flow and free cash flow still negative in 2024–2025 (though meaningfully improved versus 2021–2023). Free cash flow deterioration in 2025 (large negative growth) highlights ongoing funding needs and sensitivity to working-capital and profitability swings, even as the overall cash burn trend has moderated from prior years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	403.13M	332.31M	116.33M	75.47M	78.45M
Gross Profit	0.00	263.71M	73.07M	48.51M	64.23M
EBITDA	60.27M	7.57M	-150.11M	-176.35M	-222.14M
Net Income	-22.68M	-51.74M	-209.25M	-233.66M	-269.11M
Balance Sheet
Total Assets	465.89M	343.82M	205.80M	247.94M	381.59M
Cash, Cash Equivalents and Short-Term Investments	167.85M	144.76M	82.25M	166.86M	259.33M
Total Debt	152.22M	591.21M	540.95M	260.95M	260.20M
Total Liabilities	767.85M	732.54M	660.79M	571.72M	578.53M
Stockholders Equity	-301.96M	-388.72M	-454.99M	-323.78M	-196.94M
Cash Flow
Free Cash Flow	-12.90M	-23.97M	-135.49M	-174.83M	-263.81M
Operating Cash Flow	-13.09M	-23.65M	-135.49M	-174.83M	-263.81M
Investing Cash Flow	189.00K	-317.00K	42.50M	8.10M	-50.48M
Financing Cash Flow	36.18M	86.48M	50.46M	32.61M	268.22M

Esperion Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESPR, the sentiment is Negative. The current price of 2.7 is below the 20-day moving average (MA) of 3.24, below the 50-day MA of 3.38, and above the 200-day MA of 2.56, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 34.53 is Neutral, neither overbought nor oversold. The STOCH value of 24.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ESPR.

Esperion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	62 Neutral	$404.60M	―	39.94%	―	-0.85%	-13.50%
EBS	53 Neutral	$434.36M	12.57	9.59%	―	-29.91%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	49 Neutral	$343.52M	―	267.84%	―	15.10%	0.18%
SNDL	49 Neutral	$401.70M	―	-8.35%	―	1.76%	18.31%
ESPR	47 Neutral	$645.47M	-33.91	6.92%	―	2.83%	13.61%
ORGO	47 Neutral	$348.62M	17.73	9.56%	―	2.24%	-67.56%

Esperion Corporate Events

Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio

On March 2, 2026, Esperion Therapeutics, Inc. signed a definitive agreement to acquire privately held Corstasis Therapeutics Inc. via a merger in which Corstasis will become a wholly owned subsidiary, for an upfront cash payment of $75 million plus up to $180 million in potential regulatory and commercial milestone payments and royalties on future sales. The deal, expected to close in the second quarter of 2026 subject to customary conditions and a May 1, 2026 outside date, consolidates all Corstasis equity into cash consideration tied to upfront, contingent, and escrow-based payments and will be financed through Esperion’s existing credit facilities and royalty monetization arrangements.

Through the acquisition, Esperion will add Enbumyst, the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure and certain hepatic and renal conditions, approved in September 2025, positioning the company to target a U.S. market opportunity exceeding $4 billion and complement its existing cardiovascular franchise. Management frames the transaction as a strategic fit with Esperion’s Vision 2040, aiming to leverage its established cardiovascular commercial infrastructure to drive double-digit revenue growth, expand into outpatient heart failure and fluid overload management, and enhance its presence across metabolic, hepatic, and renal disease, while also gaining Corstasis’s subcutaneous pipeline assets for future market expansion.

On March 3, 2026, Esperion and Corstasis jointly announced the merger agreement and detailed plans to discuss the deal with investors during a conference call the same day. The companies and their advisors highlighted that the transaction’s completion remains subject to typical closing conditions, but is expected to strengthen Esperion’s long-term industry positioning in cardiovascular and renal care by adding a differentiated, home-use diuretic option that may reduce hospitalizations and broaden its stakeholder value proposition.

The most recent analyst rating on (ESPR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.